Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus
Christie Fanton(Nektar Therapeutics (United States)), Brian L. Kotzin(Howard Hughes Medical Institute), Daniel Dickerson, Jonathan Zalevsky(Nektar Therapeutics (United States)), Vishala Chindalore(Pinnacle Clinical Research), Nathan Hanan(Nektar Therapeutics (United States)), Richard Furie(Hofstra University), Robert D. Levin, Neha Dixit(Nektar Therapeutics (United States)), Isam Diab, Jacqueline A. Gibbons(Nektar Therapeutics (United States)), Cat M. Haglund(Allogene Therapeutics (United States))
Cited by 36
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654